Sonesitatug vedotin Phase 3 survival win strengthens AstraZeneca’s gastric cancer ADC strategy
Read why AstraZeneca’s sonesitatug vedotin survival win in CLDN18.2-positive gastric cancer is tempered by a Phase 3 PFS miss.
Pharma & Biotech
Pharma & Biotech
Gilead targets durable autoimmune remission with $2.18bn Ouro Medicines acquisition
Gilead Sciences acquires Ouro Medicines for up to $2.18bn, adding BCMA T cell engager gamgertamig to its inflammation pipeline. Analysis of what the deal reveals.